{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neutropenic fever"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 3-4 infections"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Any grade 3-4 toxicity"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Grade 2-4 toxicities and grade 3-4 infections among all phase I trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg)","groups":[{"description":"Clofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.","id":"OG000","title":"Phase I"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Phase I participants only","reportingStatus":"POSTED","timeFrame":"during 6 28-day cycles and 90 days out","title":"Phase I Participants: Safety","type":"SECONDARY","unitOfMeasure":"Participants"}